(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.4%.
Summit Therapeutics's revenue in 2026 is $0.On average, 19 Wall Street analysts forecast SMMT's revenue for 2026 to be $2,800,101,103, with the lowest SMMT revenue forecast at $0, and the highest SMMT revenue forecast at $12,564,556,232. On average, 19 Wall Street analysts forecast SMMT's revenue for 2027 to be $46,135,454,983, with the lowest SMMT revenue forecast at $0, and the highest SMMT revenue forecast at $146,586,489,368.
In 2028, SMMT is forecast to generate $472,116,191,960 in revenue, with the lowest revenue forecast at $8,912,458,554 and the highest revenue forecast at $1,537,263,483,054.